Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03549676 Not yet recruiting - Clinical trials for Fecal Microbiota Transplantation in GVHD

Fecal Microbiota Transplantation for Treatment of Refractory Graft Versus Host Disease-a Pilot Study

Start date: July 1, 2019
Phase: Phase 1
Study type: Interventional

The study evaluates safety and efficacy of fecal microbiota transplantation (FMT) for the treatment of refractory graft-versus-host-disease (GVHD) of the gut. FMT might be a beneficial treatment in this clinical situation with a poor prognosis and limited therapeutic options.

NCT ID: NCT03544346 Not yet recruiting - Clinical trials for Brain Health Retired Elite Athletes

Long-term Brain Health of Retired Professional Rugby Players, With a History of Concussion/Head Impact Exposure

Start date: June 18, 2018
Phase:
Study type: Observational

There has been significant recent interest on the issue of brain health in athletes. Participation in sports is generally viewed as extremely positive. Consistent evidence supports associations among exercise, cognitive vitality, neural functioning and decreased risk of cognitive decline. However, In the last decade, a dramatic shift in both public and scientific perception around the long-term consequences of concussion is evident. Rugby is a popular full-contact sport played throughout the world at varying levels of competition, including professional level. The game exposes players to inherent risk of injury including repetitive head impacts, due to the high number of collisions and tackles involved. Perhaps not surprisingly, given the physical nature of the sport, rugby has one of the highest rates of concussion of all full-contact sports. Evidence from a recent meta-anaysis found the incidence of concussion to be 4.73 per 1000 player match hours. Given the high incidence of concussion that has been reported in the literature to date, the issue of concussion and repeated head impact exposure is of particular concern in rugby. Comprehensive investigation of cognition in living retired sports persons with previous exposure to repetitive head impact is noticeably lacking in the literature to date. Findings are inconsistent and investigations are shrouded by consistent methodological biases and flaws, reducing the overall quality of the studies. Relatively little research has been conducted on the long-term effects of repetitive mild TBI or sports concussion on the retired athlete's brain health with ageing. The potential long-term consequences are poorly understood and warrant more research. This study aims to investigate the brain health of retired rugby players in comparison to retired rowers who have achieved the same levels of exercise, without exposure to SRCs

NCT ID: NCT03543683 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer Stage IV

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Start date: August 1, 2020
Phase:
Study type: Observational

The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor(EGFR-TKI) osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will occur. Previous studies show that apoptosis escape can lead to EGFR-TKI resistance.Osimertinib resistant cells show abnormal activation of PI3K/AKT/BIM activation(PMID 28765329). The classical drug aspirin can effectively decrease AKT phosphorylation and activate of BIM(PMID 28881293).So Investigators speculate that aspirin may decrease the PI3K/AKT/BIM signaling pathways, then promote osimertinib resistant cells apoptosis. The current study aims to evaluate the combination of aspirin and osimertinib in patients with EGFR/T790M mutations.

NCT ID: NCT03540810 Not yet recruiting - Clinical trials for Primary Antiphospholipid Syndrome

Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome

PAPIRUS
Start date: August 15, 2018
Phase: Phase 3
Study type: Interventional

Antiphospholipid syndrome (APS) combines thrombotic (venous and/or arterial) and/or obstetrical manifestations, along with biological anomalies related to the presence of antiphospholipid antibodies. Despite actual treatment recommended by international guidelines, the relapse rate in APS is high and survival is 65% at 15 years. Hydroxychloroquine has demonstrated its efficacy and benefits in the treatment of Systemic Lupus Erythematosus, but there is no current consensus concerning the efficacy of this treatment in the secondary prevention of thrombotic events in primary APS, even though several in vitro experimental and animal model data, along with several clinical studies have suggested a beneficial effect of this drug in this indication. Considering the prevalence of primary APS in the general population and of the number of clinical events observed in patients with primary APS and receiving conventional treatment with vitamin K anticoagulants (VKA), the consortium expects a minimum clinically relevant difference of 70%. Considering a prevalence of thrombotic events for the entire studied primary APS population of 10% at 2 years, the consortium expects a 70% decrease in thrombotic events under Hydroxychloroquine treatment administered in addition to VKA treatment in primary APS, i.e. a 3% prevalence in the Hydroxychloroquine group at 2 years. The consortium proposes a drug trial, phase III, national multicentric, comparative, randomized, superiority, double-blind, controlled with 2 compared groups (Hydroxychloroquine versus placebo) study. The enrolment period will be 24 months. The main aim of this trial is to comparatively assess at 24 months the number of new thrombotic events (venous and arterial) in primary antiphospholipid syndrome in patients treated with VKA plus Hydroxychloroquine versus VKA plus placebo, in a multicentre, prospective randomized, double-blind, versus placebo study.

NCT ID: NCT03537209 Not yet recruiting - Clinical trials for Linear Measurement Between Roots of Mandibular Premolars & Molar & IAC

Assessment Root Apex Position of Mandibular Molars and Premolars Linear to Inferior Alveolar Canal Among Egyptian Population Using CBCT

Start date: July 1, 2018
Phase:
Study type: Observational

Linear relation between premolars and molars root apex and superior border of inferior alveolar canal

NCT ID: NCT03535389 Not yet recruiting - Clinical trials for 4DCT, Knee, Femoropatellar Instability

Morphological and Biomechanical Analysis of Knee Four Dimensional CT (4DCT) in Femoropatellar Instability

EDYG
Start date: June 2019
Phase: N/A
Study type: Interventional

To compare the radiological parameters measured by dynamic four dimensional CT (4DCT) in the analysis of patellofemoral involvement of subjects (amplitude of patellofemoral tilt angle variations, coefficient of variation of the same angle, distance of lateral displacement of the patella ) in patients with patellofemoral clinical syndrome to those free of this syndrome (= control group). It is expected that the amplitude of patellofemoral tilt angle changes, its coefficient of variation, and the patella lateral displacement distance differ between the 2 groups compared. This result would clarify the potential value of dynamic 4D CT in the diagnosis of PFI

NCT ID: NCT03532698 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer Stage IV

Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)

Start date: August 1, 2020
Phase:
Study type: Observational

The third generation epidermal growth gactor receptor-tyrosine Kinase Inhibitor(EGFR-TKI) osimertinib has obvious curative effect for EGFR sensitive mutation and T790M mutation(PMID 27959700), but acquired drug resistance will occur. Previous studies show that apoptosis escape can lead to EGFR-TKI resistance.Osimertinib resistant cells show abnormal activation of PI3K/AKT/BIM activation(PMID 28765329). The classical drug aspirin can effectively decrease AKT phosphorylation and activate of BIM(PMID 28881293).So Investigators speculate that aspirin may decrease the PI3K/AKT/BIM signaling pathways, then promote osimertinib resistant cells apoptosis. The current study aims to evaluate the combination of aspirin and osimertinib in patients with EGFR/T790M mutations.

NCT ID: NCT03531931 Not yet recruiting - Clinical trials for Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety

Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial

Start date: May 2018
Phase:
Study type: Observational

Gastric cancer is the one of the leading cause of cancer death in the worldwide. Gastric cancer originates from the most superficial mucosal epithelial cells of the stomach wall, which can occur in various parts of the stomach, and can invade different depths and breadth of the gastric wall. Without chemotherapy treatment the GC patients' Median Survival Time (MST) lasts only 3-4 months. Although treated with multi-chemotherapy MST has been improved, the drugs show strong toxicities in the patients. Thus the more accurate, lower toxicity, targeted antitumor drugs are put into second-line treatment program for advanced gastric cancer. Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2), shows significant antitumor activity in the patients with GC. The purpose of this study is to determine whether apatinib plus capecitatine can improve progression free survival in patients with advanced gastric cancer.

NCT ID: NCT03531242 Not yet recruiting - Clinical trials for Venezuelan Equine Encephalomyelitis

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

VEE
Start date: June 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.

NCT ID: NCT03530735 Not yet recruiting - Xerostomia Clinical Trials

Finger-prick Autologous Blood (FAB) for Use in Dry Mouth

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

This is a feasibility study that will assess the efficacy of using autologous blood to treat moderate to severe dry mouth. Dry mouth has been estimated to affect up to 64.8% of the general population (Navazesh et al., 2009) and many patients that are affected by Sjögren's syndrome or have had radiation therapy to combat head or neck cancer (Navazesh et al., 2009). The blood will be applied to the interior of the mouth by means of a mouthwash. This research poses the first potential curative treatment for dry mouth - all other current dry mouth treatments are either symptomatic or lifestyle-based. Autologous blood has been shown to be effective in treating the epithelial surface of dry eyes. This has been attributed to the analogous growth factors in the blood to that of tears - and potentially in this case, saliva - in healing the oral epithelial surface (Herbst et al., 2004).